Certain studies have shown that specific drugs can upregulate the expression of NKG2D ligands, such as MICA/B and ULBP1‐3, in myeloma cells through DNA damage response pathways mediated by ATM and ATR. The gene discussed is MICA; the disease is plasma cell myeloma.